WO2008133198A1 - 神経突起形成促進剤 - Google Patents

神経突起形成促進剤 Download PDF

Info

Publication number
WO2008133198A1
WO2008133198A1 PCT/JP2008/057583 JP2008057583W WO2008133198A1 WO 2008133198 A1 WO2008133198 A1 WO 2008133198A1 JP 2008057583 W JP2008057583 W JP 2008057583W WO 2008133198 A1 WO2008133198 A1 WO 2008133198A1
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
neurite
formation
corneal
formation promoter
Prior art date
Application number
PCT/JP2008/057583
Other languages
English (en)
French (fr)
Inventor
Chiho Yabuta
Fumiko Yano
Mitsuyoshi Azuma
Original Assignee
Senju Pharmaceutical Co., Ltd.
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co., Ltd., Astellas Pharma Inc. filed Critical Senju Pharmaceutical Co., Ltd.
Priority to BRPI0810093-4A2A priority Critical patent/BRPI0810093A2/pt
Priority to CA2684561A priority patent/CA2684561C/en
Priority to US12/596,581 priority patent/US8637544B2/en
Priority to MX2009011250A priority patent/MX2009011250A/es
Priority to CN2008800212987A priority patent/CN101687795B/zh
Priority to ES08740638.5T priority patent/ES2577539T3/es
Priority to KR1020097024102A priority patent/KR101486605B1/ko
Priority to JP2009511854A priority patent/JP5179477B2/ja
Priority to EP08740638.5A priority patent/EP2157082B1/en
Publication of WO2008133198A1 publication Critical patent/WO2008133198A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　眼組織神経突起形成促進剤、および当該促進剤の医薬としての用途の提供。 　Ｎ－（１－アセチルピペリジン－４－イル）－４－フルオロベンズアミドまたはその薬学的に許容される塩を含有する眼組織神経突起形成促進剤、ならびにＮ－（１－アセチルピペリジン－４－イル）－４－フルオロベンズアミドまたはその薬学的に許容される塩を含有する、角膜神経突起形成促進剤および網膜神経突起形成促進剤。本発明の角膜神経突起形成促進剤は、角膜知覚の改善、ドライアイの治療または角膜上皮障害の治療に用いられる。本発明の網膜神経突起形成促進剤は、視覚機能障害の改善に用いられる。
PCT/JP2008/057583 2007-04-20 2008-04-18 神経突起形成促進剤 WO2008133198A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0810093-4A2A BRPI0810093A2 (pt) 2007-04-20 2008-04-18 Promotor de formação de nevrite
CA2684561A CA2684561C (en) 2007-04-20 2008-04-18 Neurite formation promoter
US12/596,581 US8637544B2 (en) 2007-04-20 2008-04-18 Neurite formation promoter
MX2009011250A MX2009011250A (es) 2007-04-20 2008-04-18 Promotor de la formacion de neuritas.
CN2008800212987A CN101687795B (zh) 2007-04-20 2008-04-18 轴突形成促进剂
ES08740638.5T ES2577539T3 (es) 2007-04-20 2008-04-18 Promotor de la formación de neuritas
KR1020097024102A KR101486605B1 (ko) 2007-04-20 2008-04-18 신경돌기 형성 촉진제
JP2009511854A JP5179477B2 (ja) 2007-04-20 2008-04-18 神経突起形成促進剤
EP08740638.5A EP2157082B1 (en) 2007-04-20 2008-04-18 Neurite formation promoter

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-112248 2007-04-20
JP2007112248 2007-04-20

Publications (1)

Publication Number Publication Date
WO2008133198A1 true WO2008133198A1 (ja) 2008-11-06

Family

ID=39925652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057583 WO2008133198A1 (ja) 2007-04-20 2008-04-18 神経突起形成促進剤

Country Status (11)

Country Link
US (1) US8637544B2 (ja)
EP (1) EP2157082B1 (ja)
JP (1) JP5179477B2 (ja)
KR (1) KR101486605B1 (ja)
CN (2) CN103251592B (ja)
BR (1) BRPI0810093A2 (ja)
CA (1) CA2684561C (ja)
ES (1) ES2577539T3 (ja)
MX (1) MX2009011250A (ja)
RU (1) RU2442582C2 (ja)
WO (1) WO2008133198A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6708630B2 (ja) 2015-04-17 2020-06-10 国立大学法人 東京大学 角膜障害の予防又は治療剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042011A1 (en) 1999-01-14 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2000072834A2 (en) 1999-05-28 2000-12-07 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
WO2003084542A1 (fr) 2002-04-10 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Accelerateur de production d'un facteur neurotrophique
WO2004039403A1 (ja) 2002-10-31 2004-05-13 Senju Pharmaceutical Co., Ltd. 角膜障害治療剤
JP2007112248A (ja) 2005-10-19 2007-05-10 Nissan Motor Co Ltd 駆動系の制振制御装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
CN100413538C (zh) * 2002-10-31 2008-08-27 千寿制药株式会社 角膜疾病治疗剂
WO2007104035A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042011A1 (en) 1999-01-14 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
WO2000072834A2 (en) 1999-05-28 2000-12-07 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
WO2003084542A1 (fr) 2002-04-10 2003-10-16 Fujisawa Pharmaceutical Co., Ltd. Accelerateur de production d'un facteur neurotrophique
WO2004039403A1 (ja) 2002-10-31 2004-05-13 Senju Pharmaceutical Co., Ltd. 角膜障害治療剤
JP2007112248A (ja) 2005-10-19 2007-05-10 Nissan Motor Co Ltd 駆動系の制振制御装置

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ANG ET AL., CURR OPIN OPHTHALMOL., vol. 12, 2001, pages 318
ANG, R. T. ET AL., CURRENT OPINION IN OPHTHALMOLOGY, vol. 12, 2001, pages 318 - 322
ARBELAEZ MC. ET AL., J. REFRACT SURG., vol. 18, no. 3, May 2002 (2002-05-01), pages 357 - 60
BRAGHEETH M.A. ET AL.: "Corneal sensation after myopic and hyperopic LASIK: clinical and confocal microscopic study", BR J OPHTHALMOL, vol. 89, no. 5, May 2005 (2005-05-01), pages 580 - 585, XP008121801 *
CLAO J., vol. 26, 2000, pages 159
FUJISHIMA ET AL., CORNEA, vol. 15, 1996, pages 368
KWAN Y. CHAN; RICHARD H. HASCHKE., EXP. EYE RES., vol. 41, 1985, pages 687 - 699
OTORI Y; WEI JY; BARNSTABLE CJ., INVEST. OPHTHALMOL VIS SCI, vol. 39, 1998, pages 972 - 981
See also references of EP2157082A4 *
SOLOMON, R. ET AL., THE OCULAR SURFACE, vol. 2, 2004, pages 34 - 42
TOKITA, K. ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 527, 2005, pages LLL-120
TUULI, U. L. ET AL., EXPERIMENTAL EYE RESEARCH, vol. 66, 1998, pages 755 - 763
TUULI, U. L. ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 41, 2000, pages 393 - 397
XU ET AL., CORNEA, vol. 15, 1996, pages 235
XU, K.-T. ET AL., CORNEA, vol. 15, 1996, pages 235 - 239

Also Published As

Publication number Publication date
JP5179477B2 (ja) 2013-04-10
JPWO2008133198A1 (ja) 2010-07-22
US20100144792A1 (en) 2010-06-10
CA2684561C (en) 2015-06-30
US8637544B2 (en) 2014-01-28
EP2157082A4 (en) 2011-03-30
MX2009011250A (es) 2009-11-05
KR20090130142A (ko) 2009-12-17
CA2684561A1 (en) 2008-11-06
ES2577539T3 (es) 2016-07-15
RU2442582C2 (ru) 2012-02-20
CN101687795A (zh) 2010-03-31
CN101687795B (zh) 2013-05-08
RU2009142843A (ru) 2011-05-27
KR101486605B1 (ko) 2015-01-26
EP2157082B1 (en) 2016-06-08
CN103251592A (zh) 2013-08-21
EP2157082A1 (en) 2010-02-24
BRPI0810093A2 (pt) 2014-10-21
CN103251592B (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
WO2009134371A3 (en) Composite lacrimal insert and related methods
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2009105690A3 (en) Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2006091522A3 (en) Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
WO2018033792A3 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
WO2011014587A3 (en) Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
TW200744574A (en) Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2009024677A3 (fr) Utilisation d ' acide hyaluronique pour la preparation de compositions destinees a l' amelioration de la fonction de protection de la peau, de l' oeil et des muqueuses
WO2008140052A1 (ja) ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤
EP2216019A3 (en) Ophthalmic uses of S1P receptor modulators
WO2011076368A3 (en) Topical ophthalmic peptide formulation
WO2008063639A3 (en) Compositions and methods for preserving cells of the eye
CL2007003836A1 (es) Uso de compuestos derivados de isosorbide en la prevencion y/o tratamiento de enfermedades oftalmologicas mediadas por hipertension ocular, tales como glaucoma.
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
RU2017118405A (ru) Новое лечение роговицы с применением ламинина
WO2007039123A3 (en) Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
WO2011137344A3 (en) Anti-s1p antibody treatment of patients with ocular disease
WO2013184650A3 (en) Treatment of ocular inflammatory diseases using laquinimod
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021298.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740638

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009511854

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2684561

Country of ref document: CA

Ref document number: MX/A/2009/011250

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008740638

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097024102

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009142843

Country of ref document: RU

Ref document number: 6842/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12596581

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0810093

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091020